{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-249594","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-06-01T10:30:22+00:00","discovered_at":"2026-06-01T10:35:00.338983+00:00","generated_at":"2026-06-01T10:35:36.508606+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Perspective Therapeutics updates pipeline: VMT-α-NET durable disease control; VMT01 and PSV359 progress","bullets":["VMT-α-NET (SSTR2+ NET) Phase 1/2a shows durable disease control; potential registration study at current dose level.","VMT01 (MC1R melanoma) Phase 1/2a: preliminary anti-tumor activity observed at 3.0 mCi dose.","PSV359 (FAP-ɑ solid tumors) Phase 1/2a demonstrates improved tumor retention in ongoing trial.","Integrated isotope production enables direct-to-hospital delivery and regional manufacturing for supply."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249594","json":"https://secwatch.observer/filing/0001193125-26-249594.json","markdown":"https://secwatch.observer/filing/0001193125-26-249594.md","text":"https://secwatch.observer/filing/0001193125-26-249594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526249594/0001193125-26-249594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526249594/catx-20260601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T10:35:36.508606+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0000015847-26-000009","ticker":"BUKS","company_name":"BUTLER NATIONAL CORP","filed_at":"2026-06-01T16:41:32+00:00","headline":"CEO Christopher Reedy discloses ongoing cancer treatment; remains in role","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000015847-26-000009","json":"https://secwatch.observer/filing/0000015847-26-000009.json","markdown":"https://secwatch.observer/filing/0000015847-26-000009.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/15847/000001584726000009/0000015847-26-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/15847/000001584726000009/buks-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001437749-26-018930","ticker":"CPSH","company_name":"CPS TECHNOLOGIES CORP/DE/","filed_at":"2026-06-01T13:35:50+00:00","headline":"CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share","event_type":"other_material","sec_items":["1.01","5.03","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018930","json":"https://secwatch.observer/filing/0001437749-26-018930.json","markdown":"https://secwatch.observer/filing/0001437749-26-018930.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/0001437749-26-018930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/cpsh20260528_8k.htm"},"side_by_side_evidence":null},{"accession":"0001467623-26-000040","ticker":"DBX","company_name":"DROPBOX, INC.","filed_at":"2026-06-01T13:06:23+00:00","headline":"Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program","event_type":"other_material","sec_items":["1.01","2.03","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001467623-26-000040","json":"https://secwatch.observer/filing/0001467623-26-000040.json","markdown":"https://secwatch.observer/filing/0001467623-26-000040.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1467623/000146762326000040/0001467623-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1467623/000146762326000040/dbx-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068614","ticker":"CLIR","company_name":"ClearSign Technologies Corp","filed_at":"2026-06-01T12:30:28+00:00","headline":"ClearSign Technologies prices 777,780-share public offering at $4.33/share for ~$3.37M gross proceeds","event_type":"other_material","sec_items":["1.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068614","json":"https://secwatch.observer/filing/0001104659-26-068614.json","markdown":"https://secwatch.observer/filing/0001104659-26-068614.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434524/000110465926068614/0001104659-26-068614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434524/000110465926068614/tm2615953d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0000912767-26-000035","ticker":"UFPI","company_name":"UFP INDUSTRIES INC","filed_at":"2026-06-01T12:17:02+00:00","headline":"UFP Industries authorizes $300M share repurchase program, replacing prior authorization","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000912767-26-000035","json":"https://secwatch.observer/filing/0000912767-26-000035.json","markdown":"https://secwatch.observer/filing/0000912767-26-000035.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/912767/000091276726000035/0000912767-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/912767/000091276726000035/ufpi-20260529x8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068604","ticker":"NXTC","company_name":"NextCure, Inc.","filed_at":"2026-06-01T12:10:58+00:00","headline":"NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068604","json":"https://secwatch.observer/filing/0001104659-26-068604.json","markdown":"https://secwatch.observer/filing/0001104659-26-068604.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/0001104659-26-068604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/nxtc-20260601x8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-249763","ticker":"JBIO","company_name":"Jade Biosciences, Inc.","filed_at":"2026-06-01T11:55:09+00:00","headline":"Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249763","json":"https://secwatch.observer/filing/0001193125-26-249763.json","markdown":"https://secwatch.observer/filing/0001193125-26-249763.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526249763/0001193125-26-249763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526249763/d124589d8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026522","ticker":"VRNO","company_name":"Verano Holdings Corp.","filed_at":"2026-06-01T11:15:33+00:00","headline":"Verano Announces 1-for-5 Reverse Stock Split, Reducing Shares to ~72.9M, to Facilitate U.S. Exchange Listing","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026522","json":"https://secwatch.observer/filing/0001493152-26-026522.json","markdown":"https://secwatch.observer/filing/0001493152-26-026522.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1848416/000149315226026522/0001493152-26-026522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1848416/000149315226026522/form8-k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}